Agios Pharmaceuticals | AGIO - Interest Expense On Debt

Stock Price
27.93
Daily Change
-0.23 -0.82%
Monthly
1.75%
Yearly
-17.88%
Q1 Forecast
26.59

Agios Pharmaceuticals reported $1.39B in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amgen USD 685M 9M Sep/2025
Arrowhead Research USD 21.69M 2.69M Sep/2025
Astellas Pharma JPY 3.91B 320M Mar/2025
AstraZeneca USD 303M 38M Jun/2025
Bayer EUR 762M 267M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 254M 6M Jun/2025
GlaxoSmithKline GBP 167M 17M Sep/2025
Incyte USD 592K 2K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Merck USD 327M 22M Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Novartis USD 281M 8M Sep/2025
Novartis USD 281M 8M Sep/2025
Pfizer USD 652M 2M Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025